Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Palvella Therapeutics to related companies based on the strength of its earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palvella Therapeutics | N/A | -44.44% | -36.75% |
| Palvella Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Institutional & Insider Ownership
40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Palvella Therapeutics and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Palvella Therapeutics | N/A | -$41.72 million | -25.97 |
| Palvella Therapeutics Competitors | $751.01 million | $10.42 million | -17.98 |
Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Palvella Therapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Palvella Therapeutics and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palvella Therapeutics | 1 | 0 | 14 | 1 | 2.94 |
| Palvella Therapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Palvella Therapeutics presently has a consensus target price of $214.86, suggesting a potential upside of 50.41%. As a group, “Biotechnology” companies have a potential upside of 115.37%. Given Palvella Therapeutics’ competitors higher probable upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its competitors.
Summary
Palvella Therapeutics beats its competitors on 7 of the 13 factors compared.
Palvella Therapeutics Company Profile
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
